Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck’s problems in China seem to be getting worse, raising questions about the company’s growth. Trouble with sales of Merck ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...